>

Bavarian Stock Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>BA</div>
Is it time to take up Bavarian Nordic? Bavarian Nordic Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The current investor indifference towards the small price fluctuations of Bavarian Nordic AS could raise concerns from investors as the firm closed today at a share price of 0.0 on very low momentum in volume. The company directors and management did not add any value to Bavarian Nordic investors in March. However, most investors can still diversify their portfolios with Bavarian Nordic AS to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. Check out Trending Equities.
View Stock Analysis For
Refresh
The Bavarian Nordic Stock analysis interface makes it easy to digest most current publicly released information about Bavarian Nordic as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. Bavarian stock analysis module also helps to analyze Bavarian Nordic price relationship with some important fundamental indicators such as market cap and management efficiency.

Bavarian Stock Analysis Notes

The book value of the company was currently reported as 64.94. The company recorded loss per share of 8.64. Bavarian Nordic AS had not issued any dividends in recent years. Bavarian Nordic AS, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. Bavarian Nordic AS was founded in 1994 and is based in Kvistgrd, Denmark. Bavarian Nordic operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 419 people. For more info on BAVARIAN NORDIC please contact Paul Chaplin at 45 33 26 83 83 or go to http://www.bavarian-nordic.com.

Bavarian Nordic AS Investment Alerts

Bavarian Nordic AS is not yet fully synchronised with the market data
Bavarian Nordic AS has some characteristics of a very speculative penny stock
The company reported revenue of 616.16 M. Net Loss for the year was (279.11 M) with profit before overhead, payroll, taxes, and interest of 245.5 M.
BAVARIAN NORDIC has accumulated about 1.93 B in cash with (152.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 59.99.

Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 6.2 B.

Profitablity

The company has Profit Margin (PM) of (45.3) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (46.4) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.46.

Management Efficiency

Bavarian Nordic AS has return on total asset (ROA) of (6.17) % which means that it has lost $6.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (12.63) % meaning that it generated substantial loss on money invested by shareholders.

Institutional Stock Holders for Bavarian Nordic

Bavarian Nordic Technical and Predictive Indicators

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module
Check out Trending Equities. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page